Jonathan Shaw Chad Mahan Justin Jabara Jason J. Davis
Henry Ford Health System
05-01-2019
Background: The purpose of this study was to compare the shorter-acting spinal anesthetic mepivacaine versus bupivacaine in total hip arthroplasty (THA). Methods: We retrospectively reviewed a prospec..
Background: The purpose of this study was to compare the shorter-acting spinal anesthetic mepivacaine versus bupivacaine in total hip arthroplasty (THA). Methods: We retrospectively reviewed a prospectively collected database from a single surgeon’s contemporary cohort of 312 consecutive patients undergoing primary THA. Primary outcomes were urinary retention, length of stay (LOS), neuraxial complications, pain control, and opioid consumption. Statistical analysis with univariate logistic regression was performed followed by a multivariate analysis controlling for multiple factors to evaluate the effect of anesthetic on primary outcomes. Results: The univariate analysis demonstrated those with mepivacaine had a shorter LOS (0.9 ± 0.7 vs 1.3 ± 0.7 days, P Conclusion: Mepivacaine for spinal anesthesia with THA produced a significant improvement in recovery time with less urinary complications, a shorter LOS, and a higher chance of same-day discharge. Pain was well controlled in both groups with slightly increased pain and MEQ in the early postoperative period.